AKT1 and prostate carcinoma: Given that CD97 activates ERK, protein kinase B/Akt, or RhoA signaling pathways in prostate cancer cells, researchers further explored whether the binding of CD55 to CD97 could activate the same signaling pathways in leukocytes.